New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
18:22 EDTINCYIncyte's Jakafi trials suggest survival benefits for patients with myelofibrosis
Incyte Corporation announced that several analyses from clinical studies of Jakafi were presented at the 2012 American Society of Hematology Annual Meeting. Jakafi, an oral Janus kinase, or JAK, inhibitor, is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis, or MF. In long-term results from two randomized Phase III clinical trials -- COMFORT-I and COMFORT-II -- patients with myelofibrosis treated with Jakafi had improved survival over placebo and best available therapy, suggesting an overall survival benefit. Additionally, data from an ongoing Phase II trial suggest that long-term treatment with Jakafi may be a durably efficacious therapy for patients with polycythemia vera.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
07:54 EDTINCYLeerink a buyer of Alkermes, ImmunoGen, Incyte
Subscribe for More Information
October 17, 2014
08:01 EDTINCYIncyte names Gryska CFO to succeed Hastings
Incyte announced the appointment of David Gryska as Executive Vice President and CFO, effective October 31. Gryska will succeed David Hastings, who has served as Incyte’s Executive Vice President and CFO since October 2003. Hastings, who is leaving the company to pursue other opportunities, will remain with Incyte through the end of November and will work closely with Gryska to ensure a seamless transition.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use